A recent surge in MDA5+DM cases has been observed in England in the wake of the COVID-19 pandemic, with an associated mortality rate of 32% for antimelanoma differentiation–associated gene 5 antibody–positive dermatomyositis–associated interstitial lung disease (anti-MDA5+DM-ILD) [4]. This evidence concerns the gene IFIH1 and interstitial lung disease.